It is now possible to write this comparison with much more context than would have been possible a year ago. Mounjaro launched in South Africa for type 2 diabetes in December 2024 and gained weight management approval in October 2025. Wegovy launched in August 2025. Both have been competing in the SA market for the full weight management season of late 2025 and early 2026. Pricing has shifted. Real world experience has accumulated. The picture is clearer.
This is an editorial review of where things stand in mid 2026, written for readers trying to make the decision.
The Headline Comparison
| Mounjaro | Wegovy | |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Manufacturer | Eli Lilly (SA: Aspen) | Novo Nordisk |
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 agonist only |
| SA launch | December 2024 (T2D); October 2025 (weight) | August 2025 (weight) |
| Doses | 2.5, 5, 7.5, 10, 12.5, 15 mg | 0.25, 0.5, 1, 1.7, 2.4 mg |
| Mean weight loss at max dose | ~20% | ~14-15% |
| SA cardiovascular indication | Not yet | Yes (SELECT trial) |
| SA diabetes indication | Yes | No |
| Adolescent indication (SA) | No | Yes (12+) |
| Oral contraceptive interaction | Yes (backup needed) | Minimal |
| Starting monthly cost (SA, May 2026) | ~R3,400 | ~R1,873 |
| Maintenance monthly cost (SA) | ~R5,000+ | ~R3,746 |
| Pre-pregnancy washout | ~1 month | ~2 months |
Where Mounjaro Has The Advantage
Stronger average weight reduction
The clearest single point. Head to head in SURMOUNT-5, tirzepatide produced larger weight reduction than semaglutide. Across separate trial programmes, the pattern repeats. For someone whose primary consideration is maximum possible weight loss, this is a real point in Mounjaro's favour.
Type 2 diabetes
Mounjaro is approved for type 2 diabetes in SA. Wegovy is not. Although both lower blood sugar pharmacologically, only Mounjaro is the appropriate choice when diabetes is the main indication.
Medical aid cover for diabetes
Because Mounjaro is approved for type 2 diabetes (which is on the PMB Chronic Disease List), medical aid cover is more straightforward when diabetes is the indication. Wegovy, used purely for weight management, faces the obesity-not-on-CDL problem.
Combined diabetes and weight loss
For someone with both type 2 diabetes and excess weight, Mounjaro addresses both with one medication. Wegovy is not formally indicated for diabetes in SA, although it does lower blood sugar.
Where Wegovy Has The Advantage
Cost
After Novo Nordisk's March 2026 price reductions, Wegovy is meaningfully cheaper than Mounjaro in SA. The starting Wegovy dose is around R1,873 per month, against around R3,400 for the starting Mounjaro dose. Over a year of titration and maintenance, the savings on Wegovy can run to thousands of rand. For cost sensitive patients, this is significant.
Cardiovascular indication
Wegovy holds the formal SAHPRA indication for reducing major adverse cardiovascular events in adults with established cardiovascular disease and BMI of 27 or more. Mounjaro has positive cardiovascular data from SURPASS-CVOT but the formal cardiovascular indication has not been added in SA yet. For someone with established cardiovascular disease, this currently favours Wegovy.
Adolescent indication
Wegovy is approved for adolescents aged 12 and older with obesity. Mounjaro is approved for adults only. For families considering medication for an adolescent, Wegovy is the only available option.
No oral contraceptive interaction
For women using oral contraception who do not want to change methods or add backup contraception, Wegovy avoids the issue that Mounjaro creates. This is a modest but real consideration.
Longer track record
Semaglutide has been in real world use since 2017 as Ozempic and 2021 as Wegovy. Tirzepatide entered use in 2022. Both are well studied. Semaglutide has slightly more cumulative real world data.
Discuss Which Suits Your Specific Situation
A consultation reviews your medical history, goals, and budget to recommend the right medication.
Start ConsultationWhere They Are Comparable
- Safety overall. Both have similar side effect profiles. Both are well studied.
- Practical use. Both are weekly subcutaneous injections via pre-filled pen.
- Availability in SA. Both are widely stocked by major and online pharmacies.
- Consultation process. Both can be prescribed through Online Doctor SA with the same telemedicine workflow.
- Need for long term use. Both produce weight regain on stopping. Both are intended as chronic treatment.
How To Actually Decide
The decision framework that holds up over time:
1. Define what you are optimising for
Maximum weight loss? Cost? Cardiovascular benefit in CVD? Diabetes management? Treatment of an adolescent? Each of these answers points to a different default choice.
2. Check what you cannot live without
Some considerations are firm. If the patient is an adolescent, only Wegovy works. If diabetes is the primary indication, only Mounjaro works in SA. If the budget is tight, Wegovy is significantly cheaper.
3. Consider what is reversible
You can switch between the two later. Switching is not free or easy, but it is possible. Starting one does not lock you into it forever.
4. Trust the doctor's recommendation
The consulting doctor knows the full clinical picture in a way an article cannot. A specific recommendation, taking your full medical history into account, is more useful than a generic comparison.
The Real Pattern Of Use In SA
Anecdotally in the SA prescribing market through early 2026: Mounjaro has the larger market share (52 percent of GLP-1 sales by value at end January 2026) for several reasons. It was first to market for weight management among the dual mechanism class. It has stronger trial results. Many specialists default to it for patients without specific reasons to favour Wegovy.
But Wegovy has been gaining ground since the March 2026 price reductions. The cost picture is now genuinely competitive, particularly during the early titration months. Some patients on Mounjaro have switched to Wegovy as the cost gap widened. Others have stayed with Mounjaro for the stronger trial outcomes.
The competition is good for patients. Both manufacturers are responding to the other. Both medications are likely to remain affordable relative to their international peers because of this competition. Generic semaglutide may arrive in SA by 2027 according to industry analysts, which will further shift the picture. Tirzepatide generics are not expected until the 2030s.
Frequently Asked
Mounjaro produces larger average weight reduction in head to head trials (around 20 percent at 15 mg vs around 14 percent at 2.4 mg semaglutide in SURMOUNT-5). Individual variation is wide and the difference is smaller than the averages suggest for many people.
Wegovy is currently cheaper, particularly after the March 2026 price reductions. The starting Wegovy dose is around R1,873 per month compared to around R3,400 for the starting Mounjaro dose. The gap narrows but does not close at higher doses.
Yes, under medical supervision. The new medication starts at its lowest dose and titrates up. Doses are not directly comparable between molecules, so the switch is managed clinically rather than dose-for-dose.
The side effect profiles are broadly similar. Both are GLP-1 medications and both cause similar gastrointestinal effects. Some specific differences exist (oral contraceptive interaction with Mounjaro, longer half life of semaglutide affecting pregnancy washout) but overall safety is comparable.